Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1994 Jul 15;151(2):159–166.

Periodic health examination, 1994 update: 3. Primary and secondary prevention of neural tube defects. Canadian Task Force on the Periodic Health Examination.

PMCID: PMC1336876  PMID: 7518734

Abstract

OBJECTIVE: To make recommendations on nutritional interventions and screening manoeuvres to prevent the birth of infants with neural tube defects (NTDs). OPTIONS: Folic acid consumption through diet or supplementation in women at low risk and at high risk of having a fetus with an NTD, and maternal serum alpha-fetoprotein (MSAFP) screening in low-risk pregnancies. OUTCOMES: A reduction in the incidence rate of NTDs and potentially harmful effects of false-positive results of screening tests (i.e., abortion of a normal fetus). EVIDENCE: A MEDLINE search with the use of medical subject headings "neural tube defects," "prenatal diagnosis" and "prevention and control" identified 103 original articles published between January 1979 and March 1993. Two reviewers extracted the data by applying the rules of evidence developed by the Canadian Task Force on the Periodic Health Examination. VALUES: The task force's evidence-based methods and values were used; high value was placed on prevention of NTDs and on limitation of the harmful effects of a pregnancy involving a fetus with an NTD. BENEFITS, HARMS AND COSTS: Evidence suggests that folic acid supplementation can decrease the incidence rate of NTDs in low-risk pregnancies by 40% to 60% with no adverse effects. MSAFP screening between the 16th and 18th weeks of gestation can reach a sensitivity of 83% and a specificity of 98% when it is used as part of an organized program. The effect of screening on the incidence rate of NTDs depends on whether affected fetuses are aborted. RECOMMENDATIONS: All women of childbearing age should be advised to increase their consumption of folic acid through diet or supplementation to 0.4 mg/d beginning 1 month before pregnancy and ending at the start of the second trimester. MSAFP screening is recommended in low-risk pregnancies only when it is part of a screening program that includes access to all necessary diagnostic services. High-risk women should be referred to genetic counselling before they plan a pregnancy. VALIDATION: These recommendations are comparable to the current recommendations of the US Centers for Disease Control and Prevention, the Society of Obstetricians and Gynaecologists of Canada, the Canadian Laboratory Centre for Disease Control and the Canadian College of Medical Geneticists, and they were validated through external review. SPONSOR: These guidelines were developed and endorsed by the Canadian task force, which funded by Health Canada.

Full text

PDF
159

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bower C., Stanley F. J. Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia. Med J Aust. 1989 Jun 5;150(11):613–619. doi: 10.5694/j.1326-5377.1989.tb136723.x. [DOI] [PubMed] [Google Scholar]
  2. Burton B. K., Dillard R. G., Clark E. N. Maternal serum alpha-fetoprotein screening: the effect of participation on anxiety and attitude toward pregnancy in women with normal results. Am J Obstet Gynecol. 1985 Jul 1;152(5):540–543. doi: 10.1016/0002-9378(85)90620-9. [DOI] [PubMed] [Google Scholar]
  3. Burton B. K., Dillard R. G., Clark E. N. The psychological impact of false positive elevations of maternal serum alpha-fetoprotein. Am J Obstet Gynecol. 1985 Jan 1;151(1):77–82. doi: 10.1016/0002-9378(85)90428-4. [DOI] [PubMed] [Google Scholar]
  4. Burton B. K., Sowers S. G., Nelson L. H. Maternal serum alpha-fetoprotein screening in North Carolina: experience with more than twelve thousand pregnancies. Am J Obstet Gynecol. 1983 Jun 15;146(4):439–444. doi: 10.1016/0002-9378(83)90825-6. [DOI] [PubMed] [Google Scholar]
  5. Butterworth C. E., Jr, Hatch K., Cole P., Sauberlich H. E., Tamura T., Cornwell P. E., Soong S. J. Zinc concentration in plasma and erythrocytes of subjects receiving folic acid supplementation. Am J Clin Nutr. 1988 Mar;47(3):484–486. doi: 10.1093/ajcn/47.3.484. [DOI] [PubMed] [Google Scholar]
  6. Butterworth C. E., Jr, Tamura T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr. 1989 Aug;50(2):353–358. doi: 10.1093/ajcn/50.2.353. [DOI] [PubMed] [Google Scholar]
  7. Cohen F. L. Neural tube defects: epidemiology, detection, and prevention. J Obstet Gynecol Neonatal Nurs. 1987 Mar-Apr;16(2):105–115. doi: 10.1111/j.1552-6909.1987.tb01445.x. [DOI] [PubMed] [Google Scholar]
  8. Crandall B. F., Matsumoto M. Routine amniotic fluid alphafetoprotein assay: experience with 40,000 pregnancies. Am J Med Genet. 1986 May;24(1):143–149. doi: 10.1002/ajmg.1320240118. [DOI] [PubMed] [Google Scholar]
  9. Crandall B. F., Robertson R. D., Lebherz T. B., King W., Schroth P. C. Maternal serum alpha-fetoprotein screening for the detection of neural tube defects. West J Med. 1983 Apr;138(4):524–530. [PMC free article] [PubMed] [Google Scholar]
  10. Czeizel A. E., Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992 Dec 24;327(26):1832–1835. doi: 10.1056/NEJM199212243272602. [DOI] [PubMed] [Google Scholar]
  11. Dallaire L., Michaud J., Melancon S. B., Potier M., Lambert M., Mitchell G., Boisvert J. Prenatal diagnosis of fetal anomalies during the second trimester of pregnancy: their characterization and delineation of defects in pregnancies at risk. Prenat Diagn. 1991 Aug;11(8):629–635. doi: 10.1002/pd.1970110821. [DOI] [PubMed] [Google Scholar]
  12. Drugan A., Zador I. E., Syner F. N., Sokol R. J., Sacks A. J., Evans M. I. A normal ultrasound does not obviate the need for amniocentesis in patients with elevated serum alpha-fetoprotein. Obstet Gynecol. 1988 Oct;72(4):627–630. [PubMed] [Google Scholar]
  13. Fearn J., Hibbard B. M., Laurence K. M., Roberts A., Robinson J. O. Screening for neural-tube defects and maternal anxiety. Br J Obstet Gynaecol. 1982 Mar;89(3):218–221. doi: 10.1111/j.1471-0528.1982.tb03618.x. [DOI] [PubMed] [Google Scholar]
  14. Hooker J. G., Lucas M., Richards B. A., Shirley I. M., Thompson B. D., Ward R. H. Is maternal alpha-fetoprotein screening still of value in a low-risk area for neural tube defects? Prenat Diagn. 1984 Jan-Feb;4(1):29–33. doi: 10.1002/pd.1970040105. [DOI] [PubMed] [Google Scholar]
  15. Hunter A. G. Neural tube defects in Eastern Ontario and Western Quebec: demography and family data. Am J Med Genet. 1984 Sep;19(1):45–63. doi: 10.1002/ajmg.1320190108. [DOI] [PubMed] [Google Scholar]
  16. Laurence K. M., James N., Miller M., Campbell H. Increased risk of recurrence of pregnancies complicated by fetal neural tube defects in mothers receiving poor diets, and possible benefit of dietary counselling. Br Med J. 1980 Dec 13;281(6255):1592–1594. doi: 10.1136/bmj.281.6255.1592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lippman A., Tomkins D. J., Shime J., Hamerton J. L. Canadian multicentre randomized clinical trial of chorion villus sampling and amniocentesis. Final report. Prenat Diagn. 1992 May;12(5):385–408. doi: 10.1002/pd.1970120508. [DOI] [PubMed] [Google Scholar]
  18. Luthy D. A., Wardinsky T., Shurtleff D. B., Hollenbach K. A., Hickok D. E., Nyberg D. A., Benedetti T. J. Cesarean section before the onset of labor and subsequent motor function in infants with meningomyelocele diagnosed antenatally. N Engl J Med. 1991 Mar 7;324(10):662–666. doi: 10.1056/NEJM199103073241004. [DOI] [PubMed] [Google Scholar]
  19. Macri J. N., Weiss R. R. Prenatal serum alpha-fetoprotein screening for neural tube defects. Obstet Gynecol. 1982 May;59(5):633–639. [PubMed] [Google Scholar]
  20. McCourt C. Primary prevention of neural tube defects: notice from the HPB. CMAJ. 1993 May 1;148(9):1451–1451. [PMC free article] [PubMed] [Google Scholar]
  21. Milunsky A., Alpert E. Results and benefits of a maternal serum alpha-fetoprotein screening program. JAMA. 1984 Sep 21;252(11):1438–1442. [PubMed] [Google Scholar]
  22. Milunsky A., Jick H., Jick S. S., Bruell C. L., MacLaughlin D. S., Rothman K. J., Willett W. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA. 1989 Nov 24;262(20):2847–2852. doi: 10.1001/jama.262.20.2847. [DOI] [PubMed] [Google Scholar]
  23. Mukherjee M. D., Sandstead H. H., Ratnaparkhi M. V., Johnson L. K., Milne D. B., Stelling H. P. Maternal zinc, iron, folic acid, and protein nutriture and outcome of human pregnancy. Am J Clin Nutr. 1984 Sep;40(3):496–507. doi: 10.1093/ajcn/40.3.496. [DOI] [PubMed] [Google Scholar]
  24. Nadel A. S., Green J. K., Holmes L. B., Frigoletto F. D., Jr, Benacerraf B. R. Absence of need for amniocentesis in patients with elevated levels of maternal serum alpha-fetoprotein and normal ultrasonographic examinations. N Engl J Med. 1990 Aug 30;323(9):557–561. doi: 10.1056/NEJM199008303230901. [DOI] [PubMed] [Google Scholar]
  25. Roberts C. J., Hibbard B. M., Elder G. H., Evans K. T., Laurence K. M., Roberts A., Woodhead J. S., Robertson I. B., Hoole M. The efficacy of a serum screening service for neural-tube defects: the South Wales experience. Lancet. 1983 Jun 11;1(8337):1315–1318. doi: 10.1016/s0140-6736(83)92424-8. [DOI] [PubMed] [Google Scholar]
  26. Rosenberg I. H. Folic acid and neural-tube defects--time for action? N Engl J Med. 1992 Dec 24;327(26):1875–1877. doi: 10.1056/NEJM199212243272609. [DOI] [PubMed] [Google Scholar]
  27. Sadovnick A. D., Baird P. A. A cost-benefit analysis of a population screening programme for neural tube defects. Prenat Diagn. 1983 Apr-Jun;3(2):117–126. doi: 10.1002/pd.1970030207. [DOI] [PubMed] [Google Scholar]
  28. Shojania A. M. Oral contraceptives: effect of folate and vitamin B12 metabolism. Can Med Assoc J. 1982 Feb 1;126(3):244–247. [PMC free article] [PubMed] [Google Scholar]
  29. Simmer K., Iles C. A., James C., Thompson R. P. Are iron-folate supplements harmful? Am J Clin Nutr. 1987 Jan;45(1):122–125. doi: 10.1093/ajcn/45.1.122. [DOI] [PubMed] [Google Scholar]
  30. Smithells R. W., Sheppard S., Schorah C. J. Vitamin deficiencies and neural tube defects. Arch Dis Child. 1976 Dec;51(12):944–950. doi: 10.1136/adc.51.12.944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Thunem N. Y., Lowry R. B., Tucker B. J., Medd B. W. Birth prevalence and recurrence rates of neural tube defects in southern Alberta in 1970-81. CMAJ. 1988 May 1;138(9):819–823. [PMC free article] [PubMed] [Google Scholar]
  32. Tosi L. L., Detsky A. S., Roye D. P., Morden M. L. When does mass screening for open neural tube defects in low-risk pregnancies result in cost savings? CMAJ. 1987 Feb 1;136(3):255–265. [PMC free article] [PubMed] [Google Scholar]
  33. Watson W. J., Chescheir N. C., Katz V. L., Seeds J. W. The role of ultrasound in evaluation of patients with elevated maternal serum alpha-fetoprotein: a review. Obstet Gynecol. 1991 Jul;78(1):123–128. [PubMed] [Google Scholar]
  34. Werler M. M., Shapiro S., Mitchell A. A. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA. 1993 Mar 10;269(10):1257–1261. [PubMed] [Google Scholar]
  35. Yates J. R., Ferguson-Smith M. A., Shenkin A., Guzman-Rodriguez R., White M., Clark B. J. Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects? Clin Genet. 1987 May;31(5):279–287. doi: 10.1111/j.1399-0004.1987.tb02809.x. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES